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With aim of detection the spectrum of mitochondrial DNA mutations in patients with
carotid atherosclerosis from Moscow Region, we used a Roche 454 high-throughput
sequencing of the whole mitochondrial genome. We have found that the presence of a
number of homoplasmic mitochondrial DNA mutations in genes of 16S ribosomal RNA,
subunits 2, 4, and 5 NADH dehydrogenase, subunits 1 and 2 cytochrome C oxidase,
subunit 6 ATP-synthase, tRNA- Leu 2 and cytochrome B differed between conventionally
healthy participants of the study and patients with carotid atherosclerosis. We also found
heteroplasmic mutations, including insertions one or several nucleotides, that occurred
more frequently in mitochondrial DNA of conventionally healthy participants of the study
or patients with atherosclerotic lesions.
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Introduction
Mutations of mitochondrial genome are known nowadays as one of the genetic risk factors of differ-
ent multifactorial human pathologies, including cardiovascular diseases such as CHD, myocardial
infarction, and stroke (Kofler et al., 2009; Jia et al., 2013; Szabó, 2013). Since the major morpholog-
ical basis of these diseases is atherosclerotic vascular lesions, it is possible to assume the association
of changes in the human mitochondrial genome with the risk of atherosclerosis. Recent studies
made by our scientific group showed that a number of mtDNA mutations are associated with the
presence of atherosclerotic plaques and subclinical carotid atherosclerosis (Wallace, 1994; Kofler
et al., 2009). The penetrance and expression of mitochondrial mutations may vary greatly between
relatives and depends mainly on a genotype and the level of heteroplasmy (a ratio of mutant and
normal copies of mitochondrial genome). Therefore, a quantitative assessment of a mutant allele of
mitochondrial genome is necessary for studying the association of mitochondrial mutations with
atherosclerosis.
Mitochondrial mutations may result in defects in the protein chains of respiratory enzymes and
tRNAs that are synthesized in mitochondria, which probably lead to changes in mitochondrial
function. However, the mechanisms of association of mitochondrial mutations with the forma-
tion of atherosclerotic lesions in the vascular wall still remain obscure. The present study based on
high-througput sequencing of the whole human mitochondrial genome was carried out to test the
hypothesis that mtDNA mutations can be associated with an increased risk of atherosclerosis.
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Materials and Methods
Material for this study was collected in accordance with the prin-
ciples outlined in the Declaration of Helsinki and informed, writ-
ten consent was obtained from each patient/donor. The study
was approved by the Institutional Review Board of Institute of
General Pathology and Pathophysiology, Moscow, Russian Fed-
eration; Russian Cardiology Research and Production Complex,
Moscow and Institute for Atherosclerosis Research, Skolkovo
Innovative Centre, Moscow, Russian Federation.
The studied sample included 60 individuals from Moscow
region [25male (m) and 35 female (f)] with an average age of 64.0
years (m: 63.5, f: 64.3) (Supplemental Tables 1–3). 30 patients (m:
14, f: 16) with an average age of 65.6 years were characterized by a
presence of ultrasonographically detected atherosclerotic lesions
in carotid arteries. The number of conventionally healthy partici-
pants of the study was 30 (m: 11, f: 19) with an average age of 62.4
years.
To evaluate the state of the carotid artery wall, high-resolution
B-mode ultrasonography was performed with ultrasound scan-
ner SonoScape SSI-1000 (China). Borderline carotid intima-
media thickness (CIMT) values for Moscow region were used
to characterize the presence of carotid atherosclerosis (Sobenin
et al., 2011). Persons with the presence of atherosclerotic plaque
or thickening of the intima-media layer exceeding the bound-
aries of the 75th percentile, as well as the combination of these
factors, were considered as patients with atherosclerosis (mean
CIMT 1.04 ± 0.02, m: 1.01 ± 0.02, f: 1.07 ± 0.03mm). Conven-
tionally healthy participants of the study were characterized by
CIMT values which do not exceed median values for appropriate
age group and by the absence of atherosclerotic plaques (mean
CIMT 0.69± 0.02, m: 0.75± 0.02, f: 0.66± 0.03mm).
Total DNA was extracted from whole blood by a phenol-
chloroform method with proteinase K lysis. An enrichment of
mtDNA was performed using Qiagen™ REPLI-g Mitochondrial
Kit. The amount of DNA was about 50 ng per 50µl of reaction
buffer and the yield of enriched fraction was 5µg per reaction.
The resulting enriched fraction contained DNA fragments of size
10–15 kB.
Roche 454 GS Junior Titanium system (Roche Diagnostics
GmbH) was used to carry out a high-throughput sequencing of
mitochondrial genome. 500 ng of enriched mtDNA fraction was
taken for creation a shotgun DNA fragments library and for fur-
ther sequencing. Sample preparation for sequencing was carried
out in accordance with the manufacturer’s recommendations.
Instrumental run and analysis of the sequencing quality were
performed using GS Sequencer and GS Run Browser software
(Roche Diagnostics GmbH).
Analysis of mitochondrial DNA and SNP detection was
performed using GS Reference Mapper software (Roche Diag-
nostics GmbH). The revised Cambridge reference (rCRS) of
human mitochondrial genome NC_012920.1 was used for
mapping (Andrews et al., 1999). A statistical data analysis
was performed using Microsoft Excel 2010 and IBM SPSS
Statistics v.21.0 software (http://spss.ru.joydownload.com/&
c=20?gclid=COTnxtbesLwCFaHbcgodiiMAtQ).
Results and Discussion
A pilot whole genome sequencing using 454 Roche GS Junior
Titanium system gave about 70-fold average coverage of mtDNA
which allowed to detect in the observed sample a total of 422
homoplasmic mitochondrial genome variants that differed from
rCRS. In the investigated samples we distinguished 59 mito-
chondrial genome mutations (Table 1). They were present in
over 10% of the total sample. Some of these mutations occurred
in over 10% of the sample of patients with atherosclerosis.
Meanwhile some mutations were more characteristic for over
10% of conventionally healthy participants of the study (a
control group) (Figure 1). All these mutations are known and
were reported before as markers of appropriate mitochondrial
haplogroups (van Oven and Kayser, 2009). Most of these muta-
tions (about 70%) were characterized by the higher prevalence
in the control group than in patients with atherosclerosis. As
we used rCRS as a reference, all mutations that were found
in this study can be named according to HGVS nomencla-
ture using prefix NC_012920.1. Mitochondrial mutations
m.930G>A and m.5147G>A were found only in the control
group. The presence of mutations m.14233A>G, m.185G>
A, m.11812A>G, m.14798T>C, m.16296C>T, m.146T>C,
m.462C>T, m.1811A>G, m.16126T>C, m.489T>C, m.1888G>
A, m.8697G>A, m.13708G>A, m.15928G>A, m.4216T>
C, m.11251A>G, m.15452C>A, m.195T>C, m.709G>A,
m.12612A>G, m.14905G>A, m.15607A>G, m.16069C>T, and
m.16294C>T was from 2 to 5-fold higher in control group
than in patients with atherosclerosis. This fact allows us to
assume anti-atherogenic character of these mutations. Single
nucleotide replacements m.8251G>A, m.204T>C, m.12705C>
T, and m.3010G>A were observed 1.6-fold more often in
atherosclerotic patients compared to the control group.
We also found 104 heteroplasmic mutations. Seventy two
mutations were located in the coding regions of mtDNA. It is
necessary to say that among them there were 15 insertions and
no deletions. 19 of heteroplasmic mutations were found also in
homoplasmic state. 53 mutations (22 synonymous, 22 missense,
1 nonsense, and 8 insertions) were located in genes of respiratory
chain enzymes. Most of heteroplasmic mutations were rare
variants found only in one individual. However, we found 14
most common heteroplasmic mitochondrial genome mutations
in this sample (Table 2). Mutations m.73A>G, m.295C>T,
m.4216T>C, m.9477G>A, m.15924A>G, m.16311T>C,
m.576insC, m.8516insA, m.8516insC, m.8528insA, m.8930insG,
m.10958insC, m.13047insC, and m.13050insC were found both
in the control group and in patients with atherosclerosis. There
were no statistically significant differences in the occurrence
and mean heteroplasmy level of these mutations between the
compared groups, but mutations m.8516insA, m.8516insC,
m.8930insG, m.10958insC, and m.13050insC occurred more
frequently in the control group than in atherosclerotic patients
with heteroplasmy level from 6 to 41%. Missense mutation
m.9477G>A in MT-COX3 gene and insertion m.8528insA
in MT-ATP8 occurred more frequently in patients with
atherosclerotic lesions.
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TABLE 1 | Common homoplasmic mutations, identified in the study.
Position Gene/Region Character (m, missense; s, synonymous), Name Sum in general Sum in controls Sum in atherosclerotic
for mutations in protein genes patients
73 Noncoding – m.73A>G 36 22 14
146 Noncoding – m.146T>C 4 3 1
152 Noncoding – m.152T>C 9 4 5
185 Noncoding – m.185G>A 5 4 1
195 Noncoding – m.195T>C 9 6 3
204 Noncoding – m.204T>C 4 1 3
228 Noncoding – m.228G>A 5 3 2
263 Noncoding – m.263A>G 58 29 29
462 Noncoding – m.462C>T 4 3 1
489 Noncoding – m.489T>C 7 5 2
709 RNR1 – m.709G>A 9 6 3
750 RNR1 – m.750A>G 56 27 29
930 RNR1 – m.930G>A 3 3 0
1438 RNR1 – m.1438A>G 52 27 25
1811 RNR2 – m.1811A>G 8 6 2
1888 RNR2 – m.1888G>A 7 5 2
2706 RNR2 – m.2706A>G 35 20 15
3010 RNR2 – m.3010G>A 13 5 8
3107 RNR2 – m.3107delN 57 29 28
3197 RNR2 – m.3197T>C 5 2 3
4216 ND1 m m.4216T>C 13 9 4
4769 ND2 s m.4769A>G 56 28 28
4917 ND2 m m.4917A>G 8 5 3
5147 ND2 s m.5147G>A 3 3 0
7028 COX1 s m.7028C>T 37 22 15
8251 COX2 s m.8251G>A 5 1 4
8697 ATP6 s m.8697G>A 7 5 2
8860 ATP6 m m.8860A>G 58 29 29
10398 ND3 m m.10398A>G 12 7 5
10463 TRNR – m.10463T>C 8 5 3
11251 ND4 s m.11251A>G 13 9 4
11467 ND4 s m.11467A>G 14 9 5
11719 ND4 s m.11719G>A 33 19 14
11812 ND4 s m.11812A>G 5 4 1
12308 TRNL2 – m.12308A>G 14 9 5
12372 ND5 s m.12372G>A 14 9 5
12612 ND5 s m.12612A>G 6 4 2
12705 ND5 s m.12705C>T 6 2 4
13368 ND5 s m.13368G>A 8 5 3
13617 ND5 s m.13617T>C 5 2 3
13708 ND5 m m.13708G>A 7 5 2
14233 ND6 s m.14233A>G 6 5 1
14766 CYTB m m.14766C>T 34 20 14
14798 CYTB m m.14798T>C 5 4 1
14905 CYTB s m.14905G>A 9 6 3
15326 CYTB m m.15326A>G 58 29 29
15452 CYTB m m.15452C>A 13 9 4
15607 CYTB s m.15607A>G 6 4 2
(Continued)
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TABLE 1 | Continued
Position Gene/Region Character (m, missense; s, synonymous), Name Sum in general Sum in controls Sum in atherosclerotic
for mutations in protein genes patients
15928 TRNT – m.15928G>A 7 5 2
16069 Noncoding – m.16069C>T 6 4 2
16126 Noncoding – m.16126T>C 12 9 3
16223 Noncoding – m.16223C>T 7 3 4
16256 Noncoding – m.16256C>T 5 3 2
16270 Noncoding – m.16270C>T 5 2 3
16294 Noncoding – m.16294C>T 9 6 3
16296 Noncoding – m.16296C>T 5 4 1
16304 Noncoding – m.16304T>C 5 3 2
16311 Noncoding – m.16311T>C 7 3 4
16519 Noncoding – m.16519T>C 29 15 14
FIGURE 1 | Frequency of the most common homoplasmic mtDNA mutations. For single nucleotide substitutions in coding region there is a designation of the
character of mutation (s, synonymous; m, missence), and corresponding gene.
Previously, using pyrosequencing of mtDNA fragments
with PSQ 96MA system (Biotage, Sweden) we have found
11 heteroplasmic mutations associated with atherosclerosis:
m.652delG, m.1555A>G, m.3256C>T, m.3336T>C, m.652insG,
m.5178C>A, m.12315G>A, m.14459G>A, m.13513G>A,
m.14846G>A and m.15059G>A, using NC_012920.1 as a
reference (Sazonova et al., 2009, 2014; Sobenin et al., 2013).
In the present study these mutations were not detected. It can
be possibly related with differences in sample preparation of
the compared methods. Particularly, 454 sequencing requires
high amounts of DNA per one experiment, and to obtain the
sufficient quantity of mtDNA there is a necessity to carry out
whole mitochondrial genome amplification or long-range PCR.
This stage can produce specific amplification of random mtDNA
molecules and complicate further detection of a number of
mutations with low heteroplasmy level.
In the present study with the help of next generation sequenc-
ing technology, specifically, using 454 Roche GS Junior Titanium
system, 422 homoplasmic and 104 heteroplasmic mitochondrial
genome mutations were detected. We have found that the pres-
ence of a number of homoplasmicmitochondrial DNAmutations
in genes of 16S ribosomal RNA, subunits 2, 4, and 5 NADH dehy-
drogenase, subunits 1 and 2 cytochrome C oxidase, subunit 6
ATP-synthase, tRNA- Leu 2 and cytochrome B differed between
conventionally healthy participants of the study and patients with
carotid atherosclerosis. We also found heteroplasmic mutations,
including insertions one or several nucleotides, that occurred
more frequently in mitochondrial DNA of conventionally
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TABLE 2 | Common heteroplasmic mutations, identified in the study.
Sample Heteroplasmy level
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1 0 0 0 0 0 0 0 93 0 100 0 31 0
2 16 0 0 24 0 10 0 97 0 0 0 0 100
3 0 0 0 0 0 0 0 100 0 0 0 0 0
4 19 0 0 21 0 7 11 98 0 0 0 0 0
5 0 0 0 24 0 7 0 0 0 0 0 0 99
6 0 0 0 0 0 0 0 0 0 0 0 0 0
7 0 0 0 0 0 0 0 100 0 100 0 0 0
8 0 0 0 0 0 0 0 0 0 0 0 0 0
9 0 0 0 0 0 0 0 100 0 0 0 0 0
10 0 0 11 0 11 0 0 0 0 0 0 0 2
11 0 0 0 0 0 0 0 0 0 0 0 0 0
12 0 0 0 0 0 0 0 100 0 100 0 0 0
13 0 5 15 0 0 0 0 0 0 0 0 0 0
14 0 5 6 9 0 0 0 100 0 0 0 0 0
15 0 14 0 0 0 0 0 0 0 0 0 0 0
16 0 0 0 0 0 0 0 100 0 0 0 0 0
17 0 7 8 0 13 0 0 95 0 0 0 0 100
18 0 0 0 0 0 0 0 100 0 0 77 0 0
19 0 0 0 0 0 0 0 0 0 0 0 0 100
20 0 0 0 0 0 0 0 100 0 0 0 0 0
21 0 0 0 21 0 0 4 96 0 100 0 0 0
22 0 0 0 20 0 0 0 100 0 0 0 0 0
23 0 0 0 20 0 0 0 39 89 100 0 0 0
24 0 0 0 0 0 0 0 100 0 0 0 0 0
25 0 0 0 41 0 0 0 100 0 0 0 0 0
26 0 0 0 0 0 0 0 92 56 71 0 24 27
27 0 0 0 23 0 0 2 0 0 0 0 1 0
28 0 0 0 0 0 0 0 0 0 0 0 0 0
29 0 0 0 0 0 0 0 0 0 0 0 0 0
30 0 0 0 0 0 0 0 100 0 0 0 100 0
31 0 0 12 0 0 0 0 93 0 100 0 0 0
32 0 0 0 0 0 0 0 100 0 100 0 0 0
33 0 0 7 0 0 0 0 95 0 0 73 0 0
34 0 0 0 0 0 0 0 100 0 0 0 0 0
35 0 0 9 16 0 0 0 97 0 0 72 0 0
36 0 0 9 0 0 0 0 0 0 0 0 0 0
37 0 0 0 0 0 0 0 0 0 0 0 0 0
38 0 0 0 18 0 0 0 0 0 0 0 0 0
39 0 6 9 14 0 0 4 98 0 100 0 0 0
40 0 0 0 16 0 0 0 99 0 100 0 0 0
41 0 6 0 0 0 0 0 100 61 100 0 0 0
42 0 0 0 0 0 0 0 0 0 0 0 0 86
43 0 0 0 0 0 0 0 100 0 75 0 0 0
44 0 0 0 0 18 0 0 96 85 100 0 0 0
45 0 0 0 0 0 0 0 0 0 0 0 0 0
46 0 0 0 0 0 24 0 100 0 0 0 0 0
47 31 0 0 0 0 19 9 88 0 0 0 0 0
48 0 0 0 0 0 0 0 0 0 0 0 0 0
(Continued)
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TABLE 2 | Continued
Sample Heteroplasmy level
number
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49 0 0 0 0 0 17 0 0 0 0 0 0 5
50 44 0 0 0 0 0 0 97 0 0 0 93 100
51 0 0 0 0 0 0 0 0 0 0 0 0 0
52 0 0 0 0 13 0 9 100 0 0 90 0 0
53 0 16 12 0 0 0 0 100 0 0 0 0 100
54 0 0 0 0 0 0 0 0 0 0 0 0 0
55 0 0 13 0 19 0 0 11 0 0 0 0 0
56 0 0 0 0 0 0 0 0 0 0 0 0 0
57 0 0 17 0 0 0 0 100 0 0 0 0 0
58 0 12 12 0 10 0 0 0 0 0 0 0 0
59 0 13 14 0 16 0 0 100 0 0 88 0 0
60 0 0 0 0 0 0 0 100 0 0 0 0 0
healthy participants of the study or patients with atherosclerotic
lesions.
It is necessary to mention that homoplasmic single nucleotide
replacements m.8251G>A, m.204T>C, m.12705C>T,
m.3010G>A, heteroplasmic missense mutation m.9477G>A
and insertion m.8528insA occurred more frequently in patients
with atherosclerotic lesions compared to the control group. The
findings of this study can be useful for medical geneticists and
scientists, carrying out researches in the field of cardiovascular
pathologies and atherogenesis.
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